Otaplimastat clinical trials
Also written SP-8203.
How each study uses otaplimastat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the otaplimastat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Neuroprotective Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test otaplimastat, phase 3 first.
- Mar 2027Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of CarePhase 3 · Shin Poong Pharmaceutical Co. Ltd.
Studies
Open first, then newest update. How each study uses otaplimastat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of CareRecruitingPhase 3Shin Poong Pharmaceutical Co. Ltd.NCT06660719Written as SP-8203How we know
- Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPACompletedPhase 2Shin Poong Pharmaceutical Co. Ltd.NCT04479449Written as SP-8203How we know
- Safety, Tolerability and Pharmacokinetics of SP-8203CompletedPhase 1Shin Poong Pharmaceutical Co. Ltd.NCT01757795Written as SP-8203How we know
- Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPACompletedPhase 2Shin Poong Pharmaceutical Co. Ltd.NCT02787278Written as SP-8203 High doseHow we know
Codes
What other systems call otaplimastat · ClinicalTrials.gg INT005720
- MeSH (NLM) C552779otaplimastatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) UYE03B60KAOTAPLIMASTATConfirmed FDA, NLM
- NCI Thesaurus C170269OtaplimastatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C552779 | otaplimastat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | UYE03B60KA | OTAPLIMASTAT | Confirmed FDA, NLM |
| NCI Thesaurus | C170269 | Otaplimastat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.